CELC gets approval; commercial launch planned this quarter
REVTORPYK was approved for second-line metastatic breast cancer. A commercial launch is planned for this quarter, while a supplemental NDA for PIK3CA-mutant patients is under review.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.